"Now with the approval of Revatio solution for injection, we have an option to bridge interruptions in treatment of adult patients who may be temporarily unable to take this important therapy in tablet form."

Revatio is the only phosphodiesterase 5 (PDE5) inhibitor with both oral and I.V. formulations approved in the European Union for the treatment of PAH.

Pulmonary arterial hypertension is a rare, progressive disease that affects an estimated 100,000 men and women worldwide. This incurable disease is characterized by continuous high blood pressure in the pulmonary arteries, leading to heart failure and premature death. Pulmonary arterial hypertension can occur with no known underlying cause, or it can be found in association with other disorders such as connective tissue disease.

"Pulmonary arterial hypertension is a life-threatening disease, and medical treatment can help delay damage caused by the disease," said Jean-Luc Vachiery, M.D., professor of Cardiology and director of the Pulmonary Vascular Diseases Unit at Clinique Universitaire De Bruxelles Hopital Erasme (Erasme Hospital) in Belgium and former chairman of the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. "Now with the approval of Revatio solution for injection, we have an option to bridge interruptions in treatment of adult patients who may be temporarily unable to take this important therapy in tablet form."

For some patients, continued oral medication may not be an option for a period of time. While oral treatment can often be re-introduced at a later stage, the ability to maintain treatment during periods when the patient is unable to take or tolerate an oral formulation is important to preserving health in patients with PAH. Revatio solution for injection is for adult patients with PAH who are stable on Revatio tablets but who are temporarily unable to take oral medication and for whom the physician considers continuity of treatment to be in the patients’ best interest.

"The approval of Revatio solution for injection is a clear demonstration of Pfizer's commitment to developing treatments addressing the unmet needs of patients with pulmonary arterial hypertension," said Cara Cassino, M.D., vice president of Pulmonary Vascular Disease, Clinical Development and Medical Affairs, Pfizer. "This important milestone highlights the Specialty Care Business Units dedication to advance treatments for serious and life-threatening conditions such as pulmonary vascular disease."

About Revatio
Revatio was first approved by the European Commission in October 2005. Oral Revatio tablets are available as a 20mg tablet taken three times a day. The recommended dose of Revatio Injection is 10 mg (corresponding to 12.5 mL) three times a day administered as an intravenous bolus injection.

Pfizer Inc.: Working together for a healthier world™
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.